Forbion Investor Profile: Portfolio & Exits

Forbion Overview

Investor Type
Venture Capital

Status
Active

Professionals
16

Investments
159

Portfolio
32

Exits
77

Forbion General Information

Description

Founded in 2006, Forbion is a venture capital firm headquartered in Naarden, Netherlands. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, the firm selects investments that will positively affect the health and well-being of patients. The firm also operates a joint venture with BioGeneration Ventures, which manages three separate seed and early-stage funds focused on Benelux and Germany.

Contact Information

Website

www.forbion.com

Year Founded

2006

Investor Status

Actively Seeking New Investments

Trade Association

Principles for Responsible Investment (PRI)

Primary Investor Type

Venture Capital

Other Investor Types

Growth/Expansion

Impact Investing

Primary Office

PO Box 5187
1410 AD Naarden
Netherlands

+31 035 000 0000





Forbion Investments (159)

Company Name	Deal Date	Deal Type	Deal Size	Industry	Company Stage	Lead Partner
Complement Therapeutics	23-Feb-2022	Seed Round	00.000	Biotechnology	Generating Revenue	00000-000 000000 00
0000000	23-Dec-2021	00000 00000	00000	Drug Discovery	Generating Revenue	000000 000 00.0
00000 000000	20-Dec-2021	00000 00000	0000	Drug Discovery	Clinical Trials - Phase 2	00000-000 000000 00
00000000 000000000	17-Dec-2021	00000 00000	0000	Drug Discovery	Clinical Trials - Phase 2	000000 00000000
00000000 000000000	03-Nov-2021	00000 00000	0000	Drug Discovery	Clinical Trials - Phase 3	00000-000 000000 00
0000000 (0000 0000	14-Oct-2021	00000 00000	0000	Drug Discovery	Startup	00000 0000000 00.0
0000000 000000	20-Aug-2021	0000 00000	00.000	Pharmaceuticals	Startup	00000 0000000 00.0
000000 00000000000	16-Jul-2021	0000 00000	0000	Drug Discovery	Startup	00000000 00000
NeRRe Therapeutics	07-Jul-2021	Later Stage VC	000.00	Drug Discovery	Generating Revenue	00000-000 000000 00
VectorY (Drug Discovery)	15-Jun-2021	Seed Round	000.00	Drug Discovery	Pre-Clinical Trials	00000 0000000 00.0

You’re viewing 10 of 159 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Forbion Exits (77)

Company Name	Exit Date	Exit Type	Exit Size
Gyroscope	22-Feb-2022	Merger/Acquisition	00000
0000000 00000000 0	10-Dec-2021	000	00000
00000000 000000000	31-Mar-2021	000	00000
0000 000000000000	21-Jan-2021	000000 0000000000	00000
000000000	18-Sep-2020	000000000000000000	00000
0000 000000000000	17-Sep-2020	000	00000
00000 000000000000	09-Sep-2020	000000000000000000	00000
000000000	13-Feb-2020	000000000000000000	00000
Ario Pharma	01-Oct-2019	Out of Business
Autonomic Technologies	01-Sep-2019	Merger/Acquisition

You’re viewing 10 of 77 exits. Get the full list »

Forbion Fund Performance

Fund Name	Vintage	Size	Dry Powder	DPI	RVPI	TVPI	IRR

This information is available in the PitchBook Platform. To explore Forbion‘s full profile, request access.

Request a free trial

Forbion Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Forbion Team (43)

Name	Title	Deals	Office
Vincent Van Houten	Chief Financial Officer & General Partner	0	Naarden, Netherlands
Martien van Osch	Co-Founding Partner & Managing Partner	00	Naarden, Netherlands
Geert-Jan Mulder MD	Managing Partner and Co-Founding Partner	00	Naarden, Netherlands
Sander Slootweg	Co-Founder & Managing Partner & Board Member	0	Naarden, Netherlands
Holger Reithinger Ph.D	General Partner	00	Munich, Germany